Editorial-29062026
Buyer beware: On the QR code-based drug traceability framework
India’s expanded QR code-based drug traceability framework is a necessary step, but it should not be mistaken for a complete cure to the problem of counterfeit and substandard medicines. The new rules widen the coverage beyond the earlier top 300 brands to include all vaccines, antimicrobials, narcotic and psychotropic drugs, and anti-cancer medicines, with phased compliance dates starting 1 July 2027 for most categories and 1 July 2028 for antimicrobials. That expansion is important because it targets medicines with high public-health stakes and strong misuse or diversion risks.
Why this move matters
Counterfeit and poor-quality medicines undermine trust in the health system, harm patients directly, and weaken broader goals such as antimicrobial resistance control. A QR code on the package can help a buyer, pharmacist, or regulator verify basic product details such as the name, manufacturer, batch number, manufacturing date, expiry date, and licence number. In a market as large and distributed as India’s, even modest gains in traceability can improve accountability across manufacturing, wholesaling, retail, and dispensing.
The policy also has a governance value beyond drug safety. By making key data more accessible through digital verification, it creates a paper trail that can support inspections, recalls, and enforcement action when something goes wrong. For vaccines and anti-cancer medicines in particular, where storage conditions and chain-of-custody are critical, traceability can strengthen both quality control and public confidence.
The limits of QR codes
A QR code is not the same thing as authenticity. A code can be copied, reused, relabelled, or attached to a counterfeit package unless it is backed by robust secure printing, serialisation, and backend verification systems. That means the real effectiveness of the framework depends less on the visible square on the strip and more on whether databases, scanners, alerts, and enforcement are integrated well enough to detect duplication or tampering.
There is also a practical risk of “verification theatre.” If a customer scans a code and gets only static product information, that may create a false sense of security unless the scan checks a live, unique identity against a central system. In that sense, QR codes can improve transparency, but they do not automatically stop diversion, grey-market rebranding, temperature abuse, or counterfeit distribution. The buyer must beware because the technology is only as strong as the weakest link in the supply chain.
Implementation challenges
The success of the framework will depend on industry compliance, especially among smaller manufacturers and firms with thinner margins. Printing scannable, durable, tamper-evident codes on primary or secondary packaging, integrating them with software systems, and maintaining accurate master data will impose costs and operational changes. Those costs may be manageable for large firms, but they can become a burden if timelines are tight and technical support is weak.
Another challenge is interoperability. The system must work across manufacturers, distributors, pharmacies, hospitals, and regulators, many of whom use different software and infrastructure. If scanning apps are inconsistent, if internet connectivity is weak, or if data fields are incomplete, then traceability will be patchy and enforcement uneven. The government’s phased rollout helps, but the real test will be whether systems are standardized and auditable in practice.
What consumers should do
Buyers should treat the QR code as one check, not the only check. They should also examine packaging quality, batch details, expiry date, and whether the product comes from a known pharmacy or authorized channel. If a scan fails, shows mismatched data, or reveals duplicate codes, that should be treated as a warning sign rather than a minor technical glitch.
For pharmacists and hospitals, the framework should be used to strengthen incoming-stock verification and recall readiness. For regulators, it should help identify suspicious patterns such as repeated code scans, batch anomalies, or unusually fast movement through the supply chain. In other words, the code is most useful when it is part of a disciplined verification culture.
Policy priorities ahead
To make the framework genuinely effective, three priorities stand out. First, the backend must be secure, searchable, and capable of real-time or near-real-time validation so that codes cannot simply be duplicated without detection. Second, enforcement must be risk-based, focusing on high-value, high-risk categories such as oncology, antimicrobials, vaccines, and controlled medicines where harm from counterfeit products is greatest. Third, the government should pair traceability with stronger field inspection, cold-chain monitoring, and public reporting channels so that QR verification becomes one layer in a broader safety architecture.
The policy should also be evaluated by outcomes, not by adoption counts alone. The relevant questions are whether counterfeit incidents decline, whether recalls become faster, whether pharmacists can verify products easily, and whether patient harm is reduced. If those results do not materialize, the framework will have delivered symbolism without sufficient protection.
A cautious conclusion
The QR code-based drug traceability framework is an important reform and a welcome sign that drug safety is moving up the policy agenda. But its promise should not be exaggerated: codes can be forged, systems can be gamed, and implementation gaps can hollow out even good rules. For the buyer, the message is simple: scan the code, but also stay alert to the packaging, the source, and the credibility of the supply channel.
At a policy level, the framework will succeed only if it combines technology with enforcement, transparency, and supply-chain discipline. That is the difference between traceability as a label and traceability as real consumer protection.
Download Pdf
